JP2012507994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507994A5 JP2012507994A5 JP2011535101A JP2011535101A JP2012507994A5 JP 2012507994 A5 JP2012507994 A5 JP 2012507994A5 JP 2011535101 A JP2011535101 A JP 2011535101A JP 2011535101 A JP2011535101 A JP 2011535101A JP 2012507994 A5 JP2012507994 A5 JP 2012507994A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hla
- fusion polypeptide
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 230000004927 fusion Effects 0.000 claims 12
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 6
- 108010024164 HLA-G Antigens Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 1
- 101000986079 Homo sapiens HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168675A EP2184070A1 (en) | 2008-11-07 | 2008-11-07 | HLA-G proteins and pharmaceutical uses thereof |
| EP08168675.0 | 2008-11-07 | ||
| US11280408P | 2008-11-10 | 2008-11-10 | |
| US61/112,804 | 2008-11-10 | ||
| PCT/EP2009/064575 WO2010052228A1 (en) | 2008-11-07 | 2009-11-04 | Hla-g proteins and pharmaceutical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012507994A JP2012507994A (ja) | 2012-04-05 |
| JP2012507994A5 true JP2012507994A5 (enExample) | 2012-12-06 |
Family
ID=40673439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535101A Pending JP2012507994A (ja) | 2008-11-07 | 2009-11-04 | Ｈｌａ−ｇタンパク質及びその薬学的使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110268737A1 (enExample) |
| EP (2) | EP2184070A1 (enExample) |
| JP (1) | JP2012507994A (enExample) |
| CA (1) | CA2742517A1 (enExample) |
| DK (1) | DK2352509T3 (enExample) |
| ES (1) | ES2423993T3 (enExample) |
| PT (1) | PT2352509E (enExample) |
| WO (1) | WO2010052228A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120177671A1 (en) * | 2009-06-18 | 2012-07-12 | Hla-G Technologies | Hla-g alpha 1 multimers and pharmaceutical uses thereof |
| WO2010150233A2 (en) * | 2009-06-25 | 2010-12-29 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof |
| EP3453402B1 (en) | 2012-01-12 | 2021-07-21 | Bioverativ Therapeutics Inc. | Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy |
| ES2633894T3 (es) | 2012-08-02 | 2017-09-25 | F. Hoffmann-La Roche Ag | Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas |
| KR102208505B1 (ko) | 2012-12-11 | 2021-01-27 | 앨버트 아인슈타인 컬리지 오브 메디신 | 고처리량 수용체:리간드 확인을 위한 방법 |
| WO2015112541A2 (en) * | 2014-01-21 | 2015-07-30 | Albert Einstein College Of Medicine Of Yeshiva University | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
| JP6416480B2 (ja) * | 2014-01-29 | 2018-10-31 | 国立大学法人北海道大学 | 関節リウマチまたはその関連疾患の予防または治療剤 |
| US9765330B1 (en) | 2015-01-09 | 2017-09-19 | Nant Holdings Ip, Llc | Compositions and methods for reduction of allograft recognition and rejection |
| CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US11339201B2 (en) | 2016-05-18 | 2022-05-24 | Albert Einstein College Of Medicine | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| CA3025681A1 (en) * | 2016-06-03 | 2017-12-07 | Invectys | Anti hla-g specific antibodies |
| CA3027428A1 (en) * | 2016-06-14 | 2017-12-21 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| MX2019007611A (es) | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| AU2018234628B2 (en) | 2017-03-15 | 2023-07-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2021080171A (ja) * | 2018-03-13 | 2021-05-27 | 国立大学法人北海道大学 | 改変タンパク質、医薬品、炎症性疾患の予防又は治療剤及び改変タンパク質の製造方法 |
| MX2022013208A (es) | 2020-05-12 | 2022-11-14 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2717498B1 (fr) | 1994-03-18 | 1996-05-03 | Commissariat Energie Atomique | Transcrits du gène de CMH de classe I HLA-G et leurs applications. |
| WO1999042128A1 (fr) | 1998-02-20 | 1999-08-26 | Commissariat A L'energie Atomique | Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications |
| FR2794977B1 (fr) | 1999-06-18 | 2003-10-31 | Commissariat Energie Atomique | Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention |
| FR2810047B1 (fr) | 2000-06-13 | 2004-04-02 | Commissariat Energie Atomique | Nouvelle isoforme d'hla-g et ses applications |
| RU2370276C2 (ru) * | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
| CN1968709A (zh) * | 2004-06-18 | 2007-05-23 | 瑞泽恩制药公司 | 用于治疗恶性胸腔积液的vegf抑制剂 |
| WO2007011044A1 (ja) | 2005-07-15 | 2007-01-25 | Kyushu University, National University Corporation | ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法 |
| WO2007091078A2 (en) | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| EP2027151A2 (en) * | 2006-05-15 | 2009-02-25 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
-
2008
- 2008-11-07 EP EP08168675A patent/EP2184070A1/en not_active Withdrawn
-
2009
- 2009-11-04 PT PT97478275T patent/PT2352509E/pt unknown
- 2009-11-04 JP JP2011535101A patent/JP2012507994A/ja active Pending
- 2009-11-04 EP EP09747827.5A patent/EP2352509B1/en not_active Not-in-force
- 2009-11-04 CA CA2742517A patent/CA2742517A1/en not_active Abandoned
- 2009-11-04 WO PCT/EP2009/064575 patent/WO2010052228A1/en not_active Ceased
- 2009-11-04 ES ES09747827T patent/ES2423993T3/es active Active
- 2009-11-04 DK DK09747827.5T patent/DK2352509T3/da active
- 2009-11-04 US US13/127,788 patent/US20110268737A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507994A5 (enExample) | ||
| JP2023076828A5 (enExample) | ||
| JP2019514361A5 (enExample) | ||
| JP2014519830A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| Ko et al. | An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies | |
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2016527314A5 (enExample) | ||
| JP7536294B2 (ja) | 抗体のＦｃ領域改変体 | |
| JP2019507589A5 (enExample) | ||
| JP2017501728A5 (enExample) | ||
| JP2012514997A5 (enExample) | ||
| JP2016511277A5 (enExample) | ||
| JP2013519721A5 (enExample) | ||
| JP2010227116A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| JP2019516665A5 (enExample) | ||
| TR201906652T4 (tr) | Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri. | |
| JP2020500015A5 (enExample) | ||
| JP2019504617A5 (enExample) | ||
| HRP20161542T1 (hr) | MUTIRANA Fc ANTITIJELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM | |
| JP2017527272A5 (enExample) | ||
| RU2015125639A (ru) | Удаление раковых клеток с помощью циркулирующих вирус-специфических цитотоксических т-клеток с использованием направленных против раковых клеток многофункциональных белков, содержащих молекулу гкгс класса i | |
| JP2019530441A5 (enExample) |